{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T12:49:16Z","timestamp":1740142156153,"version":"3.37.3"},"reference-count":17,"publisher":"Bentham Science Publishers Ltd.","issue":"2","funder":[{"DOI":"10.13039\/501100001871","name":"FCT","doi-asserted-by":"publisher","award":["UID\/QUI\/50006\/2019 (LAQV-REQUIMTE)","(PD\/BD\/135120\/2017)"],"award-info":[{"award-number":["UID\/QUI\/50006\/2019 (LAQV-REQUIMTE)","(PD\/BD\/135120\/2017)"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"FEDER European Union","doi-asserted-by":"publisher","award":["IF\/00092\/2014\/CP1255\/CT0004"],"award-info":[{"award-number":["IF\/00092\/2014\/CP1255\/CT0004"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UIDB\/4255\/2020"],"award-info":[{"award-number":["UIDB\/4255\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDM"],"published-print":{"date-parts":[[2021,3,24]]},"abstract":"<jats:sec>\n<jats:title>Background::<\/jats:title>\n<jats:p>Vancomycin has been in clinical use for nearly 50 years and remains the first-line treatment\noption for Gram-positive infections, including methicillin-resistant Staphylococcus aureus (MRSA).\nThere are multiple strategies to monitor therapy and adjust the dose of this antibiotic. AUC24\/MIC ratio has\nbeen demonstrated to be the best parameter to predict the effectiveness and safety of vancomycin, and a target\nratio of \u2265400 is recommended. Still, trough and peak serum levels at steady-state conditions have been used in\nclinical settings as an accurate and practical method to monitor vancomycin.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods::<\/jats:title>\n<jats:p> In this work, we collected and analyzed clinical information of patients being treated in a hospital\ncenter in Porto (Portugal) and studied the pharmacokinetics of vancomycin in silico, developing several physiologically\nbased pharmacokinetic (PBPK) models using simulation software GastroPlus\u2122. Different dosages\nand treatment regimens were studied, and the influence of patients\u2019 age, weight and renal function was evaluated;\na simulation population was also performed.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results::<\/jats:title>\n<jats:p> A linear effect of dose and a significant influence of weight and renal function in plasmatic levels of\nvancomycin was observed.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion::<\/jats:title>\n<jats:p>The results of this work corroborate the accumulation of vancomycin in plasma and identify some\nparameters that influence the pharmacokinetics of this antibiotic. The importance of therapeutic monitoring of\nvancomycin is highlighted, and the usefulness of in silico tools, namely PBPK modeling, is demonstrated.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1389200221999210101232417","type":"journal-article","created":{"date-parts":[[2021,1,5]],"date-time":"2021-01-05T09:40:55Z","timestamp":1609839655000},"page":"150-162","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["In Silico Pharmacokinetic Study of Vancomycin Using PBPK Modeling and Therapeutic Drug Monitoring"],"prefix":"10.2174","volume":"22","author":[{"given":"Abigail","family":"Ferreira","sequence":"first","affiliation":[{"name":"OncoPharma Research Group, Center for Health Technology and Services Research (CINTESIS), Rua Dr. Placido da Costa, 4200-450 Porto, Portugal"}]},{"given":"Helena","family":"Martins","sequence":"additional","affiliation":[{"name":"Departament of Pathology, Clinical Chemistry Service, Centro Hospitalar Universit\u00e1rio do Porto (CHUP), Largo Prof. Abel Salazar 4099-001, Porto, Portugal"}]},{"given":"Jos\u00e9 C.","family":"Oliveira","sequence":"additional","affiliation":[{"name":"Departament of Pathology, Clinical Chemistry Service, Centro Hospitalar Universit\u00e1rio do Porto (CHUP), Largo Prof. Abel Salazar 4099-001, Porto, Portugal"}]},{"given":"Rui","family":"Lapa","sequence":"additional","affiliation":[{"name":"LAQV\/REQUIMTE, Laboratory of Applied Chemistry, Department of Chemical Sciences, Faculty of Pharmacy, University of Porto, Rua de Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1283-1042","authenticated-orcid":true,"given":"Nuno","family":"Vale","sequence":"additional","affiliation":[{"name":"OncoPharma Research Group, Center for Health Technology and Services Research (CINTESIS), Rua Dr. Placido da Costa, 4200-450 Porto, Portugal"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1086\/491709","volume":"42","author":"Levine D.P.","year":"2006","unstructured":"Levine D.P.; Vancomycin: a history. Clin Infect Dis 2006,42(Supplement_1),S5-S12","journal-title":"Clin Infect Dis"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1093\/jac\/dkr442","volume":"67","author":"Cataldo M.A.","year":"2012","unstructured":"Cataldo M.A.; Tacconelli E.; Grilli E.; Pea F.; Petrosillo N.; Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections: systematic review and meta-analysis. J Antimicrob Chemother 2012,67(1),17-24","journal-title":"J Antimicrob Chemother"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/S0025-7125(16)30801-X","volume":"71","author":"Levine J.F.","year":"1987","unstructured":"Levine J.F.; Vancomycin: a review. Med Clin North Am 1987,71(6),1135-1145","journal-title":"Med Clin North Am"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"82","DOI":"10.2146\/ajhp080434","volume":"66","author":"Rybak M.","year":"2009","unstructured":"Rybak M.; Lomaestro B.; Rotschafer J.C.; Moellering R.; Craig W.; Billeter M.; Dalovisio J.R.; Levine D.P.; Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009,66(1),82-98","journal-title":"Am J Health Syst Pharm"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1093\/cid\/ciq146","volume":"52","author":"Liu C.","year":"2011","unstructured":"Liu C.; Bayer A.; Cosgrove S.E.; Daum R.S.; Fridkin S.K.; Gorwitz R.J.; Kaplan S.L.; Karchmer A.W.; Levine D.P.; Murray B.E.; J Rybak M.; Talan D.A.; Chambers H.F.; Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis Infectious Diseases Society of America2011,52(3),e18-e55","journal-title":"Clin Infect Dis"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/11596390-000000000-00000","volume":"51","author":"Marsot A.","year":"2012","unstructured":"Marsot A.; Boulamery A.; Bruguerolle B.; Simon N.; Vancomycin: a review of population pharmacokinetic analyses. Clin Pharmacokinet 2012,51(1),1-13","journal-title":"Clin Pharmacokinet"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1128\/AAC.03147-14","volume":"60","author":"\u00c1lvarez R.","year":"2016","unstructured":"\u00c1lvarez R.; L\u00f3pez Cort\u00e9s L.E.; Molina J.; Cisneros J.M.; Pach\u00f3n J.; Optimizing the clinical use of vancomycin. Antimicrob Agents Chemother 2016,60(5),2601-2609","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=8","first-page":"694","volume":"19","author":"Bruniera F.R.","year":"2015","unstructured":"Bruniera F.R.; Ferreira F.M.; Saviolli L.R.; Bacci M.R.; Feder D.; da Luz Gon\u00e7alves Pedreira M.; Sorgini Peterlini M.A.; Azzalis L.A.; Campos Junqueira V.B.; Fonseca F.L.; The use of vancomycin with its therapeutic and adverse effects: a review. Eur Rev Med Pharmacol Sci 2015,19(4),694-700","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1177\/2042018816638223","volume":"7","author":"Bamgbola O.","year":"2016","unstructured":"Bamgbola O.; Review of vancomycin-induced renal toxicity: an update. Ther Adv Endocrinol Metab 2016,7(3),136-147","journal-title":"Ther Adv Endocrinol Metab"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1016\/j.ajic.2006.05.227","volume":"34","author":"Rybak M.J.","year":"2006","unstructured":"Rybak M.J.; Pharmacodynamics: relation to antimicrobial resistance. Am J Infect Control 2006,34(5)(Suppl. 1),S38-S45","journal-title":"Am J Infect Control"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"e77169","DOI":"10.1371\/journal.pone.0077169","volume":"8","author":"Ye Z.K.","year":"2013","unstructured":"Ye Z.K.; Tang H.L.; Zhai S.D.; Benefits of therapeutic drug monitoring of vancomycin: a systematic review and meta-analysis. PLoS One 2013,8(10),e77169","journal-title":"PLoS One"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/imj.12036","volume":"43","author":"Avent M.L.","year":"2013","unstructured":"Avent M.L.; Vaska V.L.; Rogers B.A.; Cheng A.C.; van Hal S.J.; Holmes N.E.; Howden B.P.; Paterson D.L.; Vancomycin therapeutics and monitoring: a contemporary approach. Intern Med J 2013,43(2),110-119","journal-title":"Intern Med J"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1093\/cid\/ciu398","volume":"59","author":"Lodise T.P.","year":"2014","unstructured":"Lodise T.P.; Drusano G.L.; Zasowski E.; Dihmess A.; Lazariu V.; Cosler L.; McNutt L.A.; Vancomycin exposure in patients with methicillin-resistant Staphylococcus aureus bloodstream infections: how much is enough? Clin Infect Dis 2014,59(5),666-675","journal-title":"Clin Infect Dis"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s40262-019-00741-9","volume":"58","author":"Miller N.A.","year":"2019","unstructured":"Miller N.A.; Reddy M.B.; Heikkinen A.T.; Lukacova V.; Parrott N.; Physiologically based pharmacokinetic modelling for first-in-human predictions: an updated model building strategy illustrated with challenging industry case studies. Clin Pharmacokinet 2019,58(6),727-746","journal-title":"Clin Pharmacokinet"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1002\/psp4.33","volume":"4","author":"Wagner C.","year":"2015","unstructured":"Wagner C.; Zhao P.; Pan Y.; Hsu V.; Grillo J.; Huang S.M.; Sinha V.; Application of physiologically based pharmacokinetic (PBPK) modeling to support dose selection: report of an FDA public workshop on PBPK. CPT Pharmacometrics Syst Pharmacol 2015,4(4),226-230","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"E693","DOI":"10.3390\/biom9110693","volume":"9","author":"Ferreira A.","year":"2019","unstructured":"Ferreira A.; Lapa R.; Vale N.; Combination of gemcitabine with cell-penetrating peptides: a pharmacokinetic approach using in silico tools. Biomolecules 2019,9(11),E693","journal-title":"Biomolecules"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"Cockcroft D.W.","year":"1976","unstructured":"Cockcroft D.W.; Gault M.H.; Prediction of creatinine clearance from serum creatinine. Nephron 1976,16(1),31-41","journal-title":"Nephron"}],"container-title":["Current Drug Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/189849","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/189849\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/189849","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T16:47:41Z","timestamp":1632502061000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/189849\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,24]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3,24]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389200221999210101232417","relation":{},"ISSN":["1389-2002"],"issn-type":[{"type":"print","value":"1389-2002"}],"subject":[],"published":{"date-parts":[[2021,3,24]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-06-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-19","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}